Cargando…
Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment
Glioblastomas (GBs) frequently display activation of the epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR). mTOR exists as part of two multiprotein complexes, mTOR complex 1 (mTORC1) and 2 (mTORC2). In GBs, mTORC1 inhibitors such as rapamycin have performed poorly in c...
Autores principales: | Heinzen, Dennis, Divé, Iris, Lorenz, Nadja I., Luger, Anna-Luisa, Steinbach, Joachim P., Ronellenfitsch, Michael W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770420/ https://www.ncbi.nlm.nih.gov/pubmed/31510109 http://dx.doi.org/10.3390/ijms20184474 |
Ejemplares similares
-
Inhibition of mTOR signaling protects human glioma cells from hypoxia-induced cell death in an autophagy-independent manner
por: Divé, Iris, et al.
Publicado: (2022) -
EGFR and mTOR as therapeutic targets in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2019) -
The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma
por: Foltyn, Martha, et al.
Publicado: (2019) -
mTOR inhibition: a double-edged sword in patients with COVID-19?
por: Ghasemnejad-Berenji, Morteza
Publicado: (2021) -
Rescue of 2-Deoxyglucose Side Effects by Ketogenic Diet
por: Voss, Martin, et al.
Publicado: (2018)